We examined the role that blockage of cells in the cell cycle may play in the stimulation of gene amplification and enhancement of drug resistance. We found that several different inhibitors of DNA synthesis, which were each able to block cells at the GI-S-phase boundary, induced an enhanced cycloheximide-sensitive synthesis of an early S-phase cell cycle-regulated enzyme, dihydrofolate reductase, and of other proteins as well. This response was specific, in that blockage at the G2 phase did not result in overproduction of the enzyme. When the cells were released from drug inhibition, DNA synthesis resumed, resulting in a cycloheximide-sensitive elevation in DNA content per cell. We speculate that the excess DNA synthesis (which could contribute to events detectable later as gene amplification) is a consequence of the accumulation of S-phase-specific proteins in the affected cells, which may then secondarily influence the pattern of DNA replication.
Resistance of cultured cells to methotrexate as a result of amplification of the dihydrofolate reductase gene can be enhanced by pretreatment with a variety of agents, including metabolic inhibitors of DNA synthesis such as methotrexate (22, 25) and hydroxyurea (1, 17) , as well as agents that introduce adducts into DNA, including UV light and carcinogens (23; S. Lavi, in press). These diverse treatments have in common inhibition of DNA synthesis and progression of cells through the cell cycle. The question arises as to whether the two phenomena are related. That is, does transient blockage of cells in the cell cycle in some way promote the gene amplification events that are detectable after the inhibition of DNA synthesis is relieved?
In an initial approach to this question, Mariani and Schimke (17) showed that when synchronized CHO cells were treated in mid-S phase with hydroxyurea for 6 to 8 h and then DNA synthesis was allowed to resume during recovery of cells from the drug treatment, the level of dihydrofolate reductase enzyme increased in a subset of the cells. In addition, some cells displayed an increase in dihydrofolate reductase gene copy number that was associated with an enhanced resistance to methotrexate. Subsequently, Hill and Schimke (9) reported that following treatment of cells with hydroxyurea, the intensity of fluorescence staining of DNA per cell undergoes transient increases in a subset of the cell population and that such cells contain a variety of chromosomal aberrations. These observations have led to a model for gene amplification which proposes that transient perturbation of DNA synthesis during S phase results in overreplication of portions of the genome during the recovery period (20) . Much of the rereplicated DNA would be unstable and rapidly lost from cells; but that portion of the rereplicated DNA which underwent successful recombination to generate functional, stable genes would, when placed under appropriate selection, result in selective gene amplification and drug resistance. Such induced enhancement in the frequency of gene amplification would necessarily represent an elevation over rates of spontaneous gene amplification (12, 14) .
Nevertheless, it remains unclear how the inhibition of replicative DNA synthesis would result in an enhancement of gene amplification. Here we report the effects of variable times of DNA synthesis inhibition on the levels of dihydrofolate reductase as well as on the DNA content per cell, both during drug inhibition and following removal of the inhibitors. We found that inhibition of DNA synthesis results in a cycloheximide-sensitive accumulation of dihydrofolate reductase. Following removal of this inhibition there was a subsequent cycloheximide-sensitive increase in DNA content per cell, as determined by flow cytometry. The magnitude of the increase in DNA content was greatest following release from prolonged inhibition of synthesis and was correlated with maximal stimulation of dihydrofolate reductase enzyme accumulation.
MATERIALS AND METHODS
Growth of cells and flow cytometry. CHO cells, both sensitive (CHO K1 [no methotrexate]) and resistant (CHO K1B11 [0.5 ,uM methotrexate]; amplified approximately 50-fold for the dihydrofolate reductase gene) to methotrexate, were used in these studies. They were grown as described previously (12) in F12 medium (GIBCO Laboratories, Grand Island, N.Y.) with 10% fetal bovine serum (GIBCO), with 0 or 0.5 ,uM methotrexate, respectively. CHO cells defective in synthesis of dihydrofolate reductase (24) were also used and were grown in medium supplemented with 30 pFM each of glycine, hypoxanthine, and thymidine. All cells used were verified to be free of contamination by mycoplasm. Where indicated, cells were stained with 10 to 30 ,uM fluoresceinated methotrexate (13) Cell selection and drug treatment. Cells were treated with 1 mM hydroxyurea (1), 5 ,ug of aphidicolin per ml (except as indicated [8] ), 10 ,ug of cycloheximide per ml (16) (24) were cocultured with cells of the C3 subclone of mouse L5178Y lymphoma cells (9) . The mixed cell population was exposed to hydroxyurea for 6 h, and then coculturing was continued in the absence of the drug for an additional 12, 24, or 72 h. Following this, the nonadherent C3 cells were removed by extensive rinsing of the cultures with culture medium. Incorporation of functional mouse dihydrofolate reductase genes by the CHO cells was then measured by examining their acquisition of competence to form colonies during growth for 3 weeks in medium not supplemented with glycine, thymidine, or hypoxanthine (7) . As a control, the CHO cells were transfected directly with DNA prepared from the C3 cells, as described previously (7) .
In parallel experiments, C3 cells were prelabeled for 36 h with [3H]thymidine (0.025 ,uCi/ml) and then cocultured for 12 to 72 h with hydroxyurea-treated dihydrofolate reductasenegative CHO cells. After removal by rinsing of the nonadherent C3 cells, the CHO cells were arrested in metaphase with Colcemid (2 h), and chromosome spreads were prepared for autoradiography (Kodak NTB-2 emulsion). Transfer of labeled DNA was measured by counting silver grains over chromosomes. For each sample, 50 to 200 metaphase spreads were counted.
Measurement of dihydrofolate reductase enzyme and mRNA. To measure dihydrofolate reductase synthesis, cells were pulse-labeled for 0.5 h with [35S]methionine as described previously (18) and proteins were separated electrophoretically by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and analyzed by autoradiography. Autoradiographic signals were quantitated by integrating densitometry on a Joyce-Loebl Chromoscan III with background correction. mRNA content was determined by the isolation of total RNA from treated or control cells, separation by electrophoresis in formaldehyde-agarose gels, and hybridization to 32P-labeled mouse dihydrofolate reductase probe (2) .
RESULTS
Increase in dihydrofolate reductase levels during prolonged S-phase block. The experiments cited above (1, 17) (13) .
In Fig. 1 ( Fig. 2a) . This slight discrepancy may be accounted for by the long incubation period required for the equilibration of fluoresceinated methotrexate across the cell membrane. On removal of hydroxyurea from the culture medium, the rate of dihydrofolate reductase synthesis gradually returned to control levels, but even after 18 h of recovery this rate was still elevated fourfold (Fig. 3a, lane 5) . In addition to dihydrofolate reductase, at least five other bands (the identities of which are presently unknown) showed an increase in labeling intensity in drug-treated cells (Fig. 3a, arrowheads) . Thus, the effect of the inhibition of DNA synthesis is not limited to dihydrofolate reductase.
The increase in dihydrofolate reductase content during treatment with hydroxurea can be blocked by cycloheximide. Cells were treated for 12 h with hydroxyurea in the presence or absence of cycloheximide; the brief period of treatment was necessary to avoid cytotoxic effects of the cycloheximide. Hydroxyurea treatment induced, as before, an increase in fluoresceinated methotrexate staining intensity ( Fig. 4a versus b) , which was abolished by cotreatment with cycloheximide (Fig. 4d) . Cycloheximide alone had no effect on fluorescence staining of these cells (Fig. 4c) .
S phase block increases dihydrofolate reductase mRNA levels. The amount of dihydrofolate reductase mRNA in cells treated with hydoxyurea is shown in Fig. 5 . The level of mRNA increased dramatically in cells treated for 24 h, an elevation which is consistent with the increased rate of enzyme synthesis (Fig. 3) and accumulation of enzyme (Fig.   2 ). When hydroxyurea was removed, the level of dihydrofolate reductase mRNA remained elevated for at least 24 h. In contrast, we observed no enhancement in levels of hydroxymethylglutaryl coenzyme A reductase or c-myc mRNA levels but found an approximate twofold increase in P-actin mRNA content in treated cells (data not shown). The amount of dihydrofolate reductase mRNA also increased in cells treated for 24 h with aphidicolin, although the degree of the increase was not as great (four-to fivefold; data not shown) as that seen when cells were treated with hydroxyurea.
Cells treated with hydroxyurea have an increased DNA content following resumption of DNA synthesis. A prediction arising from previous studies (17) Fig. 1 , and then prepared cells for flow cytometric measurement of DNA content either immediately or after a period of recovery from the inhibition of DNA synthesis. As expected, prolonged inhibition (24 h) of DNA synthesis, followed by recovery (24 h) of synthesis, resulted in a significant increase in DNA fluorescence staining intensity per cell (Fig. 6d versus f) , with some cells showing elevations in DNA staining to three of more times the level during the G2 phase (Fig. 6f) . Brief inhibition (1 h) of DNA synthesis, followed by recovery for 24 h (Fig. 6e) did not elicit a measurable increase in DNA staining, however.
Surprisingly, cells exposed to prolonged treatment with inhibitors of DNA synthesis displayed measurable increases in DNA staining intensity, even without periods of recovery from drug exposure. When aphidicolin was continuously applied for 42 h and DNA staining was examined immediately without recovery of the cells in the absence of drug, the staining intensity of DNA was nevertheless elevated (Fig. 6a  versus c) . Even with only 24 h of exposure to the inhibitor, DNA staining intensity was also elevated, although the enhancement was not as great (Fig. 6b) We also wished to determine whether the elevation in DNA staining intensity following administration of inhibitors of DNA synthesis could be blocked by protein synthesis inhibitors. We therefore treated cells with both aphidicolin and cycloheximide for 18 h and then compared DNA staining profiles after 24 h (Fig. 6h) or 72 h (Fig. 6i) of recovery in the absence of either drug with the DNA staining profile of control untreated cells (Fig. 6g) . We found that the increase in DNA staining intensity after 24 h of recovery was almost completely abolished by the cycloheximide, and the fluorescence profile returned to control levels by 72 h. The slight shift in staining observed in Fig. 6h may be accounted for by the partial synchronization of the cell population under these conditions. At neither time was the dramatic increase in cell size or DNA content observed to be at the level as that which occurred in the absence of the cycloheximide cotreatment (Fig. 6f) (Fig. 6) .
Finally, we used spectrofluorimetric methods to verify the apparent increases in DNA content per cell revealed by flow cytometry. CHO cells were treated with aphidicolin (1 ,ug/ml) for 18 h, released from the inhibition for 24 Treatment of cells with Colcemid does not induce an increase in dihydrofolate reductase content. To determine whether blockade at other points in the cell cycle would induce responses similar to those described above, asynchronously growing populations of cells were treated with Colcemid for 18 h and then analyzed for staining with fluoresceinated methotrexate or Hoechst 33342 dye. Although this concentration of Colcemid was sufficient to completely prevent mitosis, resulting in an accumulation of cells in the G2 phase of the cell cycle (Fig. 7d versus c) , no increase in DNA staining was observed above the normal G2-phase level. Similarly, the staining with fluoresceinated methotrexate also showed no increase above the level to be expected from an increase in cell size ( Fig. 7b versus a) . This result indicates that the increase in fluorescence staining that we observed is not simply a consequence of a prolonged block in the progression of cells through the cell cycle. Rather, it arises specifically from the blockage of cells in the S phase of the cell cycle.
Frequency of formation of methotrexate-resistant colonies increases with hydroxurea treatment. We wished to establish a relationship between the development of resistance to methotrexate and the increase in DNA content following the exposure of cells to hydroxyurea. Cells were treated with hydroxyurea for 18 h, allowed to recover in the absence of hydroxyurea for 12 h, sorted according to DNA staining intensity, and then exposed to selection with 100 nM methotrexate. When colonies resistant to methotrexate were counted after 3 weeks, we found that the cell population displaying increased DNA content showed a 10-fold enhancement in the frequency of resistance when compared with cells not exposed to hydroxyurea (Table 2) . (9) treated asynchronously growing L5178Y cells with hydroxyurea for 6 h and found that after recovery some cells had elevated DNA content. It was this subset of cells that displayed frequent chromosomal aberrations in the first M phase following resumption of DNA synthesis, and it was from these cells that a high frequency of methotrexate resistance was generated.
One explanation of these results is that the initial event in the induction of gene amplification by hydroxyurea is the rereplication of the dihydrofolate reductase genes, from which elevated levels of dihydrofolate reductase and methotrexate resistance subsequently derive (17) . Another explanation, not mutually exclusive of the first, is that some of the increase in dihydrofolate reductase could instead arise from altered expression patterns of the parental copies of dihydrofolate reductase genes. The results of the study presented here are consistent with the second of the two possible explanations.
We found that prolonged inhibition of DNA synthesis with aphidicolin, hydroxyurea, or methotrexate resulted in the cycloheximide-sensitive accumulation of dihydrofolate reductase (Fig. 1, 2, and 4) . This accumulation was a consequence of elevated dihydrofolate reductase synthetic rates (Fig. 3) , which in turn resulted from an increase in dihydrofolate reductase mRNA levels (Fig. 5) . The increase in dihydrofolate reductase content was not observed, however, when cells were blocked in the G2 phase of the cell cycle by treatment with Colcemid (Fig. 7) . Previous workers (3) have also noted a methotrexate-inducible accumulation of dihydrofolate reductase enzyme, although the degree of enhancement was not as great as that reported here (presumably because of the brief exposure of their cells to methotrexate). Our results considerably extend their observations, and we argue that the basis for the increase in enzyme levels rests at least in part with the marked elevation in dihydrofolate reductase mRNA levels in the treated cells (Fig. 5) . However, we cannot exclude the possibility that altered rates of translation or of degradation of the dihydrofolate reductase protein may also contribute to the enhancement that we observed.
Similarly, we do not yet know whether the increase in the dihydrofolate reductase mRNA levels reflects an induction by drug treatment of increased transcription, decreased degradation, or accumulation due to prolonged periods of synthesis of mRNA at normal rates. Some insight into these questions may be gained from a consideration of the cell cycle regulation of the dihydrofolate reductase gene. The rate of synthesis of dihydrofolate reductase protein is low during the G, phase and increases markedly at the onset of the S phase (18) . Results of recent studies (5) have indicated [4] ) is transcriptionally activated. It is possible, then, that disruption of the cell cycle by agents that block cells at the G1-S-phase boundary could result in preferential accumulation of proteins expressed from such cell cycleregulated genes, which would thereby be activated for an artifically prolonged period.
An additional point is that the concentrations of hydroxyurea and aphidicolin used in these experiments do not inhibit DNA synthesis completely. Indeed, on prolonged inhibition there was a progressive recovery of [3H]thymidine incorporation into DNA (1). The mechanism for this apparent resumption of DNA synthesis is not known, although two possibilities may be considered. First, alterations in nucleotide pools that occur normally during the S phase (10) and during drug treatments (19) may decrease the effectiveness of inhibition by hydroxyurea and aphidicolin. DNA polymerase alpha inhibition by aphidicolin is competitive with deoxynucleotide triphosphates (11) , and a similar phenomenon may occur by an unspecified mechanism for hydroxyurea inhibition of ribonucleotide reductase. A second possibility is that ribonucleotide reductase and DNA polymerase alpha enzyme levels might also increase in a fashion similar to that of dihydrofolate reductase during periods of inhibition of DNA synthesis, thus overcoming the inhibitory effects of these drugs.
In either case, we propose that treatment of cells with inhibitors of DNA synthesis results in the generation of cells which are arrested at a point in the cell cycle when the dihydrofolate reductase gene is transcriptionally activated. Indeed, P. J. Farnham and R. T. Schimke (submitted for publication) have shown that nuclei prepared from cells blocked with aphidicolin initiate transcription in vitro of the dihydrofolate reductase gene 10 to 50 times more actively than do nuclei from untreated cells. Cells blocked at this point in the cell cycle may have increased transcriptional capacity for a battery of genes, of which the dihydrofolate reductase gene is only one (in Fig. 3 enhanced synthesis of several unknown abundant proteins is shown) and the products of which may participate in the initiation and progression of DNA synthesis in the cell cycle. When such enzymes are present in excess, overreplication of DNA may occur when synthesis of DNA is allowed to resume.
Consistent with this, we also found that on release of cells from drug inhibition the resumption of DNA synthesis is associated with the cycloheximide-sensitive elevation of levels of DNA fluorescence staining (Fig. 6) . We believe that this represents a true increase in DNA content per cell and is not an artifact of the experimental conditions we employed. Thus, the increase is detected as enhanced cellular staining by either of two different DNA-specific fluorescent dyes. In addition, the increase cannot be accounted for either by fusion of treated cells or by uptake of DNA released from dying cells, nor is it consistent with enhanced binding of fluorescent dyes by damaged or unfolded DNA (15) ; it is instead associated with a variety of chromosomal abnormalities that include the appearance of abundant extrachromosomal material visible in the light microscope (9) . In other studies, antibody directed against bromodeoxyuridine incorporated into DNA has been used to demonstrate overreplication following exposure of cells to hypoxia (19a) , and microspectrophotometric analyses of cells exposed to methotrexate also have revealed net increases in DNA content (6) . We therefore consider the increase in DNA fluorescence staining most likely to represent true increases in DNA content in the treated cells. In addition, the increase in DNA content is maximal during the recovery from prolonged inhibition of DNA synthesis and is correlated with maximal enhancement of dihydrofolate reductase enzyme levels. That is, DNA content does not increase following brief periods of inhibition of DNA synthesis (Fig. 6e) , nor following cell cycle block in the G2 phase (Fig. 7d) ; these are conditions that do not result in elevated levels of dihydrofolate reductase.
The conditions of drug exposure employed here included some that were more extreme than those used earlier to elicit dihydrofolate reductase gene amplification and methotrexate resistance (1, 17) . Thus, although these conditions are effective in inducing marked increases in dihydrofolate reductase and DNA content, they also cause considerable cell death (Table 2) . It was therefore necessary to verify that even these harsh treatments could still enhance the generation of drug resistance in cells. We found that when CHO cells were treated with hydroxyurea and then sorted for elevated DNA content, such cells were enriched for subsequent resistance to methotrexate (Table 2 ). This result confirms results of earlier work with mouse L5178Y cells (9) .
The data presented here raise a fundamental question concerning an aspect of the regulation of DNA replication: What determines the number and timing of initiations of DNA replication once a cell is committed to the S phase and, in particular, when DNA replication patterns are perturbed by cytotoxic drugs or environmental agents? We have presented elsewhere (21) a model for the generation of chromosomal aberrations and rearrangements based on initial overreplication of DNA and subsequent recombination events, including, but not limited to, gene amplification. We suggest that disruptions in DNA synthesis, with consequent accumulations of cell cycle-regulated enzymes involved in DNA synthesis, may actually facilitate the later DNA overreplication and chromosomal abnormalities that accompany these events.
